Biomaterials Translational ›› 2021, Vol. 2 ›› Issue (1): 19-29.doi: 10.3877/cma.j.issn.2096-112X.2021.01.004

• REVIEW • Previous Articles     Next Articles

Recombinant adeno-associated virus-based gene therapy combined with tissue engineering for musculoskeletal regenerative medicine

Yiqing Wang, Xiangyu Chu, Bing Wang*()   

  1. Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Received:2020-09-09 Revised:2021-01-10 Accepted:2021-01-11 Online:2021-03-31 Published:2021-03-28
  • Contact: Bing Wang E-mail:bingwang@pitt.edu


Recombinant adeno-associated viral (rAAV) vector-mediated gene delivery is a novel molecular therapeutic approach for musculoskeletal disorders which achieves tissue regeneration by delivering a transgene to the impaired tissue. In recent years, substantial scientific progress in rAAV gene therapy has led to several clinical trials for human musculoskeletal diseases. Nevertheless, there are still limitations in developing an optimal gene therapy model due to the low transduction efficiency and fast degradation of the gene vectors. To overcome the challenges of rAAV gene therapy, tissue engineering combined with gene therapy has emerged as a more promising alternative. An rAAV viral vector incorporated into a biomaterial has a more controlled gene expression, lower immune response, and higher efficiency. A number of biomaterials and architectures have been combined with rAAV viral vectors, each having its own advantages and limitations. This review aims to give a broad introduction to combinatorial therapy and the recent progress this new technology has offered.

Key words: gene therapy, musculoskeletal regeneration, rAAV, stem cell, tissue engineering